IP Library Granted Patent US 10,590,482
Granted Patent B2
US 10,590,482 · App. 16/399,957 · Granted Mar 17, 2020

Amplification of cell-free DNA using nested PCR

Inventors: Allison Ryan (Belmont, CA); Styrmir Sigurjonsson (San Jose, CA); Milena Banjevic (Los Altos Hills, CA); George Gemelos (Portland, OR); Matthew Hill (Belmont, CA); Johan Baner (San Francisco, CA); Matthew Rabinowitz (San Francisco, CA); Zachary Demko (San Francisco, CA)
Assignee: Natera, Inc.
C12Q1/6869C12Q1/6876G16B10/00C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,590,482
App. No.
16/399,957
Granted
Mar 17, 2020
Kind
B2
Abstract

Methods for non-invasive prenatal paternity testing are disclosed herein. The method uses genetic measurements made on plasma taken from a pregnant mother, along with genetic measurements of the alleged father, and genetic measurements of the mother, to determine whether or not the alleged father is the biological father of the fetus. This is accomplished by way of an informatics based method that can compare the genetic fingerprint of the fetal DNA found in maternal plasma to the genetic fingerprint of the alleged father.

Claims (23)

1. A method for nested PCR amplification, comprising:

isolating cell-free DNA from a biological sample and ligating adaptors to the isolated cell-free DNA, wherein the adaptors each comprise a universal priming site;

performing a first PCR to simultaneously amplify at least 10 target loci using a universal primer and at least 10 target-specific primers in a first reaction volume; and

performing a second, nested PCR to simultaneously amplify the at least 10 target loci using the universal primer and at least 10 inner target-specific primers in a second reaction volume to obtain amplified DNA, wherein primer binding sites of the inner target-specific primers of the second PCR are internal to primer binding sites of the target-specific primers of the first PCR, wherein at least 80% of the amplified DNA maps to the target loci.

2. The method of claim 1 , wherein the biological sample is a blood, plasma, serum, or urine sample.

3. The method of claim 1 , wherein at least one of the primers comprises a sequencing tag.

4. The method of claim 1 , wherein the PCR is one-sided nested PCR.

5. The method of claim 1 , wherein the first PCR comprises simultaneously amplifying at least 50 target loci using the universal primer and at least 50 target-specific primers in the first reaction volume.

6. The method of claim 1 , wherein the first PCR comprises simultaneously amplifying at least 100 target loci using the universal primer and at least 100 target-specific primers in the first reaction volume.

7. The method of claim 1 , wherein the second PCR comprises simultaneously amplifying at least 50 target loci using the universal primer and at least 50 inner target-specific primers in the second reaction volume.

8. The method of claim 1 , wherein the second PCR comprises simultaneously amplifying at least 100 target loci using the universal primer and at least 100 inner target-specific primers in the second reaction volume.

9. The method of claim 1 , wherein the concentration of each target-specific primer of the first and/or second PCR is less than 20 nM.

10. The method of claim 1 , wherein the concentration of each target-specific primer of the first and/or second PCR is less than 10 nM.

11. The method of claim 1 , wherein the length of the annealing step of the first and/or second PCR is at least 3 minutes.

12. The method of claim 1 , wherein the length of the annealing step of the first and/or second PCR is at least 5 minutes.

13. The method of claim 1 , wherein at least 90% of the amplified DNA maps to the target loci.

14. The method of claim 1 , wherein the target loci are SNP loci.

15. The method of claim 1 , wherein the cell-free DNA comprises DNA from a fetus.

16. The method of claim 1 , wherein the cell-free DNA comprises DNA from a tumor.

17. The method of claim 1 , wherein the cell-free DNA comprises DNA from a transplant.

18. The method of claim 1 , wherein the adaptors each comprise a molecular barcode.

19. The method of claim 18 , wherein the isolated cell-free DNA are tagged with up to 1024 different molecular barcodes.

20. The method of claim 18 , wherein the isolated cell-free DNA are tagged with 1024-65536 different molecular barcodes.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2021
From: ZIMMERMANN, BERNHARD
To: GENE SECURITY NETWORK, INC.
Reel/Frame 056586/0371 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2020
From: RYAN, ALLISON; SIGURJONSSON, STYRMIR; BANJEVIC, MILENA; GEMELOS, GEORGE; HILL, MATTHEW; BANER, JOHAN; RABINOWITZ, MATTHEW; DEMKO, ZACHARY
To: GENE SECURITY NETWORK, INC.
Reel/Frame 051541/0017 →
CHANGE OF NAME Recorded Jan 16, 2020
From: GENE SECURITY NETWORK INC.
To: NATERA, INC.
Reel/Frame 051626/0556 →
Continuity (13)
Continuation 16012667 · Jun 19, 2018
Continuation 13335043 · Dec 22, 2011
Continuation In Part 13300235 · Nov 18, 2011
Continuation In Part 13110685 · May 18, 2011
Provisional Application 61426208 · Dec 22, 2010
Provisional Application 61571248 · Jun 23, 2011
Provisional Application 61542508 · Oct 3, 2011
Provisional Application 61395850 · May 18, 2010
Provisional Application 61398159 · Jun 21, 2010
Provisional Application 61462972 · Feb 9, 2011
Provisional Application 61448547 · Mar 2, 2011
Provisional Application 61516996 · Apr 12, 2011
Related Publication 20190256907A1 · Aug 22, 2019
Cited By (9)
US 12,195,803 US 12,209,281 US 12,252,743 US 12,281,354 US 12,442,038 US 12,462,935 US 12,534,759 US 12,553,082 US 12,662,697